Pacira BioSciences, Inc. (PCRX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $24.00. The rating moved from Neutral to Oversold on August 8, 2026.

• Public ratingOversold (as of August 19, 2026)
• Last close$24.00
• Last changeMoved from Neutral to Oversold on August 8, 2026
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic

See all oversold Healthcare stocks →

AI analysis

Pacira’s revenues remain closely linked to surgical volumes and hospital adoption of opioid‑sparing protocols; near‑term sentiment is constructive but fundamental upside depends on margin recovery, commercial traction beyond Exparel, and defense against pricing pressure. Payer rationalization and competitive threats are the main constraints. Absent new clinical readouts or material portfolio diversification, expect near-term trading to be driven by procedure volume trends, payer decisions, and broader market risk appetite.

Key factors

• Core franchise centered on Exparel (liposomal bupivacaine) benefits from recovery in elective surgical volumes and continued hospital focus on opioid-sparing pain management.
• Limited product diversification increases sensitivity to competitive and reimbursement dynamics; commercial execution on adoption and share gains is critical.
• Payer environment tightening and strategic cost-management initiatives across health systems could pressure pricing and adoption despite clinical benefits.
• Recent risk-on market sentiment and rotation into growth names may provide near-term technical support and trading interest.
• Insider activity (Form 4) and lack of major new filings in the window provide little fresh fundamental disclosure; visibility into pipeline and new launches remains limited.

Risks

• Generic entrants or therapeutic substitutes that erode pricing or market share for Exparel.
• Accelerated payer push to limit utilization or impose stricter coverage criteria, including hospital formulary substitution.
• High reliance on a single or small number of products leading to revenue concentration risk.
• Procedure-volume volatility (elective surgery slowdowns) driven by macro or pandemic-related shocks.
• Regulatory, litigation, or manufacturing supply disruptions that could impact product availability or introduce costs.

Latest MarketMoodz coverage

• Pacira Faces Board Fight as Activist Targets CEO Pay, Missed Earnings2026-03-12

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.